Treatment of prostate cancer with hormonal therapy in Europe

BJU International

Volumn 103, Issue SUPPL. 2, 2009, Pages 2-6

  Miller, Kurt ^a   Anderson, John ^b   Abrahamsson, Per Anders ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; DIETHYLSTILBESTROL; ESTROGEN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GOSERELIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ACUTE HEART INFARCTION; ANDROGEN DEPRIVATION THERAPY; ANTIANDROGEN THERAPY; BONE ATROPHY; BONE DENSITY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASTRATION; CEREBROVASCULAR ACCIDENT; CLINICAL PROTOCOL; CONGESTIVE HEART FAILURE; DEEP VEIN THROMBOSIS; DRUG HYPERSENSITIVITY; ERECTILE DYSFUNCTION; EUROPE; GYNECOMASTIA; HOT FLUSH; HUMAN; LIBIDO DISORDER; LONG TERM CARE; LUNG EMBOLISM; MASTALGIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SIDE EFFECT;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; DRUG ADMINISTRATION SCHEDULE; EARLY DIAGNOSIS; EUROPE; HUMANS; INCIDENCE; MALE; PRACTICE GUIDELINES AS TOPIC; PROSTATIC NEOPLASMS;

EID: 60649098643     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08382.x     Document Type: Review

References (30)

1. World Health Organization. The Global Burden of Disease: 2004 Update. Available at: http://www.who.int/healthinfo/global-burden-disease/GBD-report- 2004update-full.pdf. Accessed January 2009
2. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007 18 : 581 92
3. Heidenrich A, Aus G, Abbou CC et al. Guidelines on Prostate Cancer. European Association of Urology 2007-2008. Available at: http://www.uroweb.org/ fileadmin/tx-eauguidelines/Prostate%20Cancer.pdf. Accessed January 2009
4. Horwich A, Parker C, Kataja V. Prostate cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008 19 (Suppl. 2 ii45 6
5. National Institute for Health and Clinical Excellence (NICE). Prostate cancer: diagnosis and treatment. Full Guideline February 2008. Available at: http://www.nice.org.uk/nicemedia/pdf/CG58FullGuideline.pdf. Accessed January 2009
6. Klotz LH, Goldenberg SL, Jewett MA et al. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol 2003 170 : 791 4
7. Schulman CC, Debruyne FM, Forster G, Selvaggi FP, Zlotta AR, Witjes WP. 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol 2000 38 : 706 13
8. Aus G, Abrahamsson PA, Ahlgren G et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int 2002 90 : 561 6
9. Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 2006 4 : CD006019
10. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999 341 : 1781 8
11. Abrahamsson PA, Anderson J, Boccon-Gibod L, Schulman C, Studer UE, Wirth M. Risks and benefits of hormonal manipulation as monotherapy or adjuvant treatment in localised prostate cancer. Eur Urol 2005 48 : 900 5
12. Studer UE, Whelan P, Albrecht W et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 2006 24 : 1868 76
13. Studer UE, Collette L, Whelan P et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 2008 53 : 941 9
14. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000 355 : 1491 8
15. Boccon-Gibod L, Hammerer P, Madersbacher S, Mottet N, Prayer-Galetti T, Tunn U. The role of intermittent androgen deprivation in prostate cancer. BJU Int 2007 100 : 738 43
16. Bruchovsky N, Klotz L, Crook J et al. Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: clinical parameters. Cancer 2006 107 : 389 95
17. Irani J, Celhay O, Hubert J et al. Continuous versus six months a year maximal androgen blockade in the management of prostate cancer: a randomised study. Eur Urol 2008 54 : 382 91
18. Tunn U. The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: putting IAD under the spotlight. BJU Int 2007 99 (Suppl. 1 19 24
19. Miller K, Steiner U, Lingnau A et al. Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer. J Clin Oncol 2007 25 (Suppl.): Abstract No. 5015
20. Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol 2004 22 : 2546 53
21. Seidenfeld J, Samson DJ, Hasselblad V et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000 132 : 566 77
22. Debruyne FM. Gonadotropin-releasing hormone antagonist in the management of prostate cancer. Rev Urol 2004 6 (Suppl. 7 S25 32
23. Boccon-Gibod L, Klotz L, Schröder H et al. Degarelix compared to leuprolide depot 7.5 mg in a 12-month randomised, open-label, parallel-group Phase III study in prostate cancer patients. Eur Urol Suppl 2008 7 : 205
24. Damber JE, Aus G. Prostate cancer. Lancet 2008 371 : 1710 21
25. Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol 1997 157 : 439 44
26. Stoch SA, Parker RA, Chen L et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 2001 86 : 2787 91
27. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002 168 : 1005 7
28. Michaelson MD, Kaufman DS, Lee H et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007 25 : 1038 42
29. Smith MR, Malkowicz SB, Chu F et al. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol 2008 179 : 152 5
30. Smith MR, Malkowicz SB, Chu F et al. Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study. J Clin Oncol 2008 26 : 1824 9